| 1 |
Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: A practice guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society[J]. Ther Drug Monit, 2018,40(6):663-674.
|
| 2 |
Hashemizadeh Z, Badiee P, Malekhoseini SA, et al. Observational study of associations between voriconazole therapeutic drug monitoring, toxicity and outcome in liver transplant patients[J]. Antimicrob Agents Chemother, 2017,61(12):e01211-e01217.
|
| 3 |
Park WB, Kim NH, Kim KH, et al. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial[J]. Clin Infect Dis, 2012,55(8):1080-1087.
|
| 4 |
Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2016,71(7):1772-1785.
|
| 5 |
Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation[J]. Annu Rev Pharmacol Toxicol, 2006,46(1):123-149.
|
| 6 |
Vreugdenhil B, van der Velden WJFM, Feuth T, et al. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole[J]. Br J Clin Pharmacol, 2018,84(9):1980-1988.
|
| 7 |
Encalada Ventura MA, Span LF, van den Heuvel ER, et al. Influence of inflammation on voriconazole metabolism[J]. Antimicrob Agents Chemother, 2015,59(5):2942-2943.
|
| 8 |
van Wanrooy MJ, Span LF, Rodgers MG, et al. Inflammation is associated with voriconazole trough concentrations[J]. Antimicrob Agents Chemother, 2014,58(12):7098-7101.
|
| 9 |
Goutelle S, Bourguignon L, Bleyzac N, et al. In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates[J]. AAPS J, 2013,15(2):415-426.
|
| 10 |
Dolton MJ, Ray JE, Chen SC, et al. Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring[J]. Antimicrob Agents Chemother, 2012,56(9):4793-4799.
|
| 11 |
Imataki O, Yamaguchi K, Uemura M, et al. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients[J]. Transpl Infect Dis, 2018,20(4):e12886.
|
| 12 |
Czock D, Keller F, Rasche FM, et al. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids[J]. Clin Pharmacokinet, 2005,44(1):61-98.
|
| 13 |
Chen Y, Ferguson SS, Negishi M, et al. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter[J]. Mol Pharmacol, 2003,64(2):316-324.
|
| 14 |
Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients[J]. Antimicrob Agents Chemother, 2010,54(10):4424-4431.
|
| 15 |
Lin XB, Li ZW, Yan W, et al. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients[J]. Br J Clin Pharmacol, 2018,84(7):1587-1597.
|
| 16 |
Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients[J]. Antimicrob Agents Chemother, 2010,54(2):852-859.
|
| 17 |
李春. 实用临床药物动力学[M]. 成都：四川大学出版社，1997.
|
| 18 |
Chiu KW, Nakano T, Hu TH, et al. Homogenous phenomenon of graft liver CYP2C19 genotypes after living donor liver transplantation[J]. Eur J Clin Invest, 2012,42(4):352-356.
|
| 19 |
Chiu KW, Nakano T, Chen KD, et al. Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation[J]. PLoS One, 2013,8(8):e71314.
|
| 20 |
Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,63(4):e1-e60.
|
| 21 |
Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management[J]. Eur Respir J, 2016,47(1):45-68.
|
| 22 |
Hamada Y, Tokimatsu I, Mikamo H, et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring[J]. J Infect Chemother, 2013,19(3):381-392.
|
| 23 |
Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology[J]. J Antimicrob Chemother, 2014,69(5):1162-1176.
|